Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial
収録刊行物
-
- The Lancet Infectious Diseases
-
The Lancet Infectious Diseases 19 (10), 1091-1100, 2019-10
Elsevier BV